Solid Biosciences INC Form 4 insider transactions

Solid Biosciences Inc. reports that Director Ilan Ganot was granted stock options for 77,500 shares.

Perceptive Advisors LLC, along with related entities and individuals, has reported the acquisition of stock options for Solid Biosciences Inc. common stock.

Director Georgia Keresty of Solid Biosciences Inc. acquired stock options for 77,500 shares, with an exercise price of $6.61, as part of a compensation plan.

Solid Biosciences Inc. reports that Director Martin I. Freed acquired 77,500 stock options with an exercise price of $6.61.

Clare Kahn, a Director at Solid Biosciences Inc., acquired 77,500 stock options with an exercise price of $6.61.

Solid Biosciences Inc. reports that Director Lynne Marie Sullivan acquired 77,500 stock options on June 10, 2026, with an exercise price of $6.61.

Adam Leo Stone, a Director at Solid Biosciences Inc., acquired stock options representing 77,500 shares of common stock.

Solid Biosciences reports the vesting of 79,341 Restricted Stock Units for Chief Operating Officer David T. Howton following the achievement of a performance milestone.

Gabriel Brooks, Chief Medical Officer of Solid Biosciences Inc., reported the vesting of 58,847 performance stock units on January 29, 2026, tied to a business objective milestone.

Solid Biosciences Inc. reports a significant vesting event for its President and CEO, Alexander Cumbo, related to performance stock units.

Paul Herzich, Chief Technology Officer at Solid Biosciences Inc., reported the vesting of 54,925 Restricted Stock Units (RSUs) on January 29, 2026, tied to performance milestones.

Director Ian F. Smith acquired 3,441 shares of Solid Biosciences Inc. common stock through the vesting of restricted stock units.

Solid Biosciences Inc. CEO Alexander Cumbo reported the sale of 16,644 common shares to cover tax withholdings following the vesting of restricted stock units.

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax withholding.

Solid Biosciences Director Ilan Ganot reported the vesting of restricted stock units and a subsequent tax-related sale of shares.

Solid Biosciences' Chief Technology Officer, Paul Herzich, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Solid Biosciences' Chief Operating Officer, David T. Howton, sold 7,469 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Solid Biosciences' Chief Medical Officer, Gabriel Brooks, reported the vesting of 10,937 restricted stock units and a subsequent sale of 5,563 shares to cover tax obligations.

Solid Biosciences CFO Kevin Tan sold 5,404 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Solid Biosciences' Chief Operating Officer, David T. Howton, sold 18,894 shares of common stock to cover tax withholdings related to RSU vesting, not as a discretionary trade.

Solid Biosciences President and CEO Alexander Cumbo executed a non-discretionary sale of 48,913 common shares to cover tax obligations from restricted stock unit vesting.

Solid Biosciences Director Ilan Ganot sold 7,205 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Solid Biosciences CFO Kevin Tan sold 14,783 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Solid Biosciences' Chief Medical Officer, Gabriel Brooks, sold 12,616 shares of common stock to cover tax withholding related to RSU vesting.

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, sold 12,348 shares of common stock to cover withholding taxes related to vested restricted stock units.

Solid Biosciences' Chief Technology Officer, Paul Herzich, sold 10,905 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Solid Biosciences CFO Kevin Tan reported the vesting of performance and restricted stock units, alongside a tax-related sale of common stock.

Solid Biosciences CEO Alexander Cumbo reported recent equity transactions, including vesting of performance and restricted stock units, new option and RSU grants, and a tax-related stock sale.

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, reported the vesting of performance and restricted stock units, new equity grants, and a tax-related share sale.

Solid Biosciences Chief Medical Officer Gabriel Brooks reported the vesting of performance and restricted stock units, new option grants, and a tax-related stock sale.